ALNY
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Alnylam receives Health Canada approval for AMVUTTRA® (vutrisiran), first RNAi therapeutic for ATTR amyloidosis cardiomyopathyDec 16, 2025
- Alnylam announces first patient dosed in ZENITH global Phase 3 cardiovascular outcomes trial of ZilebesiranOct 1, 2025
- New data from HELIOS-B Phase 3 study demonstrate lower rates of gastrointestinal events in ATTR-CM patients treated with VutrisiranSep 29, 2025
- Alnylam announces HELIOS-B Phase 3 data showing Vutrisiran reduces mortality and cardiovascular events in ATTR-CM through 48 monthsSep 2, 2025
- Alnylam receives EU approval for AMVUTTRA® (vutrisiran) to treat ATTR amyloidosis with cardiomyopathyJun 9, 2025